Cardiac Dysfunction - Prevention and Monitoring in Cancer Survivors
Key Points
Key Points
Heart failure (HF), presenting during or after completion of cancer treatment, is a well-recognized complication that begins with risk factors known to be associated with the development of HF, including the toxicity of chemotherapy and/or radiation (stage A), and is commonly progressive after structural changes to the heart occur.
The initial manifestation may be asymptomatic.
Onset may also be responsible for interruption or discontinuation of cancer-directed therapy, potentially reducing the chance for long-term survival.
Risk
...Risk...
...ded that cancer patients who meet any of...
...mendation can be made on the risk of ca...
Prevention
...Prevention...
...Prevention PRIOR TO Initi...
...d or minimize the use of potentially...
...hould perform a comprehensive asse...
...Prevention DUR...
...ns should screen for and actively manage...
...linicians may incorporate a number of...
...s who require mediastinal RT which might...
Surveillance
...Surveillance...
...Monitoring During...
...ould complete a careful history and physical e...
...mmendation 4.2...
Echocardiogram for diagnostic work-up ( EB ,...
...magnetic resonance imaging (MRI) or mul...
...cardiac biomarkers (troponins, natriuret...
...ardiologist based on findings. (EB...
...veillance imaging may be offered durin...
...dations can be made regarding cont...
...may use routine echocardiographic sur...
...Monit...
...cians should complete a careful histor...
...mendation 5.1.1...
...hocardiogram for diagnostic work-up ( EB ,...
...rdiac MRI or MUGA if echocardiogram...
...iac biomarkers (troponins, natriuretic pe...
...o a cardiologist based on findings (I...
...n echocardiogram may be performed 6–12 months...
...iac MRI or MUGA may be offered for surveillan...
...ts identified to have asymptomatic cardiac dy...
...ations can be made regarding the f...
...ans should regularly evaluate and manage cardiovas...